Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UD9H
|
|||
| Former ID |
DNC009072
|
|||
| Drug Name |
AM-281
|
|||
| Synonyms |
AM 281; 202463-68-1; AM281; AM-281; UNII-SBP4A4DYH2; SBP4A4DYH2; 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide; CHEMBL476833; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholin-4-ylpyrazole-3-carboxamide; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholino-1H-pyrazole-3-carboxamide; Tocris-1115; AC1N7ICF; GTPL741; SCHEMBL1517458; CTK8E9266; CHEBI:93039; AJFFBPZYXRNAIC-UHFFFAOYSA-N; MolPort-003-940-033; HMS3267K18; EX-A1546; ZINC2575699; BCP07951; BN0064
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H19Cl2IN4O2
|
|||
| Canonical SMILES |
CC1=C(N(N=C1C(=O)NN2CCOCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)I
|
|||
| InChI |
1S/C21H19Cl2IN4O2/c1-13-19(21(29)26-27-8-10-30-11-9-27)25-28(18-7-4-15(22)12-17(18)23)20(13)14-2-5-16(24)6-3-14/h2-7,12H,8-11H2,1H3,(H,26,29)
|
|||
| InChIKey |
AJFFBPZYXRNAIC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 202463-68-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6319092, 9633964, 11113926, 14963226, 24724384, 29215036, 35590691, 57356906, 78939620, 85229929, 85788638, 91702814, 103632291, 104114218, 104231684, 104253241, 112831392, 126602131, 127414551, 134346277, 135649928, 135697593, 136345205, 141403573, 162022968, 162248550, 163124178, 204380364, 227720041, 241050887, 241182141, 241375224, 250130890, 251962113, 251971031, 252159963, 252214708, 252265250
|
|||
| ChEBI ID |
CHEBI:93039
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Inhibitor | [2] |
| Cannabinoid receptor 2 (CB2) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Rap1 signaling pathway | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| BDNF signaling pathway | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 741). | |||
| REF 2 | Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.